EVGN — Evogene Ltd.

Evogene Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Total revenues for the first nine months of 2025 were approximately $3.5 million, down from $4 million in the same period of 2024. Q3 2025 revenues were about $300,000, a decline from $1.7 million year-over-year.
• Operating Loss: The operating loss for the first nine months was approximately $8.8 million, significantly improved from $15.3 million in the same period last year. Q3 operating loss was approximately $2.7 million, down from $5.9 million in Q3 2024.
• Net Loss: The net loss for the first nine months was approximately $2.5 million, compared to $18 million in the previous year. Q3 net income was approximately $5.2 million, a turnaround from a net loss of $8.2 million in Q3 2024, primarily due to income from discontinued operations.
• Cash Position: As of September 30, 2025, cash and short-term deposits totaled approximately $16 million, bolstered by the sale of Lavie Bio's assets.

2. Strategic Updates and Business Highlights

• Strategic Shift: Evogene is transitioning towards computational chemistry, focusing on generative design of small molecules for pharmaceutical and agricultural applications through its ChemPass AI technology.
• Cost Reduction: A significant organizational change and cost reduction plan was implemented, leading to lower operating expenses of approximately $2.9 million in Q3 2025, down from $6.6 million in Q3 2024.
• Subsidiary Developments: The sale of Lavie Bio's majority assets to ICL was completed in July 2025, contributing to a gain of approximately $6.4 million recognized in the financials. AgPlenus continues to work on developing new herbicides and fungicides in collaboration with major industry players like Bayer and Corteva.

3. Forward Guidance and Outlook

• Future Collaborations: Evogene anticipates announcing new collaborations in the pharmaceutical sector, particularly with biotech companies, in early 2026.
• Growth Potential: The company aims to leverage its ChemPass AI technology to enhance drug discovery success rates and expects to continue expanding its partnerships in both the pharmaceutical and agricultural sectors.
• Market Positioning: Evogene is focused on establishing itself as a leader in AI-driven small molecule design, with a strong emphasis on addressing real-world challenges in both industries.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The decrease in revenue, particularly from AgPlenus, raises concerns about the sustainability of income streams, especially following the one-time payment from Bayer in early 2024.
• Market Risks: The ongoing geopolitical situation in Israel, including the war between Israel and Hamas, poses risks to operational stability and could impact future business activities.
• Dependency on Collaborations: The success of Evogene's strategy heavily relies on securing partnerships in the pharmaceutical sector, which may take time to materialize.

5. Notable Q&A Insights

• Interest in ChemPass AI: Management noted increased interest in their AI technology following industry developments, such as NVIDIA and Eli Lilly's partnership, indicating a growing market for AI in drug discovery.
• IR Strategy: There was acknowledgment of the need for improved investor relations efforts, with plans for roadshows and participation in professional events to enhance visibility.
• Upcoming Catalysts: Expected announcements include new collaborations in both pharma and agriculture, as well as potential partnerships with major tech firms to enhance ChemPass AI capabilities.

Overall, Evogene's Q3 2025 results reflect a strategic pivot towards computational chemistry and AI-driven solutions, with significant improvements in financial metrics but ongoing challenges in revenue generation and market risks.